Report Content
Chapter 1 Methodology
1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Carrier screening industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 Technology trends
2.1.5 Medical condition trends
2.1.6 End-use trends
Chapter 3 Carrier Screening Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rise in awareness coupled with emphasis on early diagnosis of genetic disorders
3.2.1.2 Surging adoption of IVF and cryopreservation
3.2.1.3 Technological advancements in carrier screening
3.2.1.4 Growing consumer interest in personalized medicines
3.2.2 Industry pitfalls & challenges
3.2.2.1 High costs and reimbursement issues of carrier testing
3.2.2.2 Lack of standard guidelines and skilled professionals
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By technology
3.3.3 By medical condition
3.3.4 By end-use
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Future market trends
3.7 Marketing strategy analysis
3.8 Technology landscape
3.9 Reimbursement scenario
3.10 Policy landscape
3.11 Gap analysis
3.12 Porter’s analysis
3.13 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix
4.4 Vendor matrix analysis
4.5 Strategy dashboard, 2022
Chapter 5 Carrier Screening Market Size and Forecast, By Type (USD Million)
5.1 Key trends, type
5.2 Expanded Carrier Screening
5.2.1 Predesigned Panel Testing
5.2.2 Customized Panel Testing
5.3 Targeted Disease Carrier Screening
Chapter 6 Carrier Screening Market Size and Forecast, By Technology (USD Million)
6.1 Key trends, technology
6.2 DNA sequencing
6.3 Polymerase chain reaction
6.4 Microarrays
6.5 Others
Chapter 7 Carrier Screening Market Size and Forecast, By Medical Condition (USD Million)
7.1 Key trends, medical condition
7.2 Pulmonary conditions
7.3 Hematological conditions
7.4 Neurological conditions
7.5 Others
Chapter 8 Carrier Screening Market Size and Forecast, By End-use (USD Million)
8.1 Key trends, end-use
8.2 Hospitals
8.3 Reference laboratories
8.4 Physician offices & clinics
8.5 Others
Chapter 9 Carrier Screening Market Size and Forecast, By Region (USD Million)
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Sweden
9.3.8 The Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Indonesia
9.4.7 Philippines
9.4.8 Vietnam
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Columbia
9.5.5 Chile
9.5.6 Peru
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Turkey
9.6.5 Israel
9.6.6 Iran
Chapter 10 Company Profiles
10.1 Fulgent Genetics Inc.
10.2 Illumina Inc.
10.3 Diasorin S.p.A.
10.4 Natera Inc.
10.5 Thermo Fisher Scientific Inc.
10.6 Eurofins Scientific
10.7 Myriad Genetics, Inc.
10.8 Opko Health Inc
10.9 Quest Diagnostics Inc.
10.10 InVitae Corporation
10.11 Abbott Laboratories
10.12 Danaher Corporation ( Cepheid)
10.13 Sema4
10.14 Gene by Gene, Ltd.
10.15 BGI Genomics
